Gastrointestinal Therapeutics Market Size to Reach $52.41 Billion by 2029 | Growth at 5.5% CAGR Forecast

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

What is the Projected Market Size of the Gastrointestinal Therapeutics Industry?
There has been significant expansion in the market size of gastrointestinal therapeutics in the past few years. The market value is expected to escalate from $39.99 billion in 2024 to $42.30 billion in 2025, witnessing a compound annual growth rate (CAGR) of 5.8%. Factors contributing to the growth in the historical period include increased government spending on healthcare, a growth in early detection rates, heightened public awareness of gut health, a rise in digestive disorders related to lifestyle, and the augmentation of multidisciplinary treatment strategies.

What Will Be the Size of the Gastrointestinal Therapeutics Market by 2029?
It is anticipated that the market size for gastrointestinal therapeutics will experience considerable expansion in the coming years. The market will elevate to $52.41 billion by 2029, with a compound annual growth rate (CAGR) of 5.5%. The projected growth during this forecast period is a result of increased demand for biologics and targeted treatments, growing acceptance of personalized medicine, patient propensity towards combination therapies, heightened focus on microbiome-oriented therapeutics, and an increase in gastrointestinal complications associated with antibiotics. The main trends for this forecasted period involve the incorporation of technology in endoscopy devices, the development of microbiome-focused therapies, digital health and remote monitoring integration, multi-omics data incorporation in therapeutic development, and innovations in acid suppression treatments.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

What Are the Key Drivers Accelerating Growth in the Gastrointestinal Therapeutics Market?
The growth of the gastrointestinal therapeutics market is anticipated to be driven by the increasing prevalence of inflammatory bowel diseases (IBD). IBD, including primary conditions like Crohn's disease and ulcerative colitis, is a chronic disease that incites inflammation in the digestive tract. A combination of genetic predisposition leading to an abnormal immune response to gut microbes contributes to the increase of these diseases. Gastrointestinal therapeutics are employed to control and treat these bowel diseases by targeting the root inflammation, modulating digestive functions, and relieving related symptoms, thereby enhancing patient outcomes. To exemplify, data from the IBD Registry, a non-profit organization based in the UK, revealed that in December 2023, over 5,300 individuals were registered with IBD, a surge of more than 3,000 members compared to 2022. Consequently, the upsurge in inflammatory bowel diseases is contributing to the expansion of the gastrointestinal therapeutics market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

How Is the Gastrointestinal Therapeutics Market Segmented by Type, Application, and Region?
The gastrointestinal therapeutics market covered in this report is segmented -

1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics
2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

Subsegments:
1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products
2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

What Are the Key Trends Driving Growth in the Gastrointestinal Therapeutics Market?
Leading firms in the gastrointestinal therapeutics market are prioritizing the development of novel therapies like sustained-release (SR) fixed-dose combination capsules. These advancements are expected to boost treatment efficiency and patient adherence. These SR fixed-dose combination capsules are orally administered medicines that progressively release various active compounds to sustain steady drug concentrations and minimize dosage frequency. In 2024, Akums Drugs and Pharmaceuticals Limited, a pharmaceutical preparation manufacturing company in India, introduced rabeprazole + levosulpiride SR capsules into the Indian market for the treatment of gastrointestinal disorders. The formulation merges rabeprazole, a proton pump suppressant known to reduce stomach acidity, with levosulpiride, a prokinetic compound that enhances gut movement. In unison, these components effectively alleviate issues such as heartburn, acid reflux, bloating, and indigestion. This combination is commonly recommended for the management of gastroesophageal reflux disease, peptic ulcers, and various other associated gastrointestinal (GI) disorders.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25768&type=smp

Who Are the Leading Companies Driving Growth in the Gastrointestinal Therapeutics Market?
Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, Olympus Corporation, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy's Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

Which Is the Leading Region in the Global Gastrointestinal Therapeutics Market?
North America was the largest region in the gastrointestinal therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Speak With Our Expert: Saumya Sahay: Americas +1 310-496-7795: Asia +44 7882 955267 & +91 8897263534: Europe +44 7882 955267: Email: saumyas@tbrc.info: The Business Research Company - www.thebusinessresearchcompany.com: Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.